</s><s><s><s> the availability of human papillomavirus ( hpv ) bivalent ( types 16, 18) vaccines provides an opportunity to decrease the burden of cervical cancer, other anogenital cancer precursors and cancers, and genital warts in the united states. 
 although data on efficacy against oropharyngeal cancer endpoints from clinical trials are not available, vaccination is likely to be effective for prevention of orophagia-attributable cervical cancer. in late 2011, 
 the us department of health and human services updated recommendations for routine vaccination of males aged 11 or 12 years and for those aged 13 through 21 years not previously vaccinated. </s>